Month: November 2022

EdiGene_Logo_Updated_Version

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent ?-thalassemia

BEIJING & WALTHAM, Mass.--(BUSINESS WIRE)--EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for...

Dr_Charmaine_Gittleson_Patrys_Chairman_of_the_Board_of_Directors

Patrys Appoints Global Biotechnology Leader as Chairman – In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy

MELBOURNE, Australia--(BUSINESS WIRE)--Patrys Limited (ASX: PAB, “Patrys” or the “Company”), a therapeutic antibody development company, has announced the appointment of...